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ORIGINAL ARTICLE

Synthesis, Molecular Docking and Biological Evaluation
of Some Quinazolinone Analogs
Benu Kumari, Suvarna G Kini*, Muhammad Mubeen
Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences,
Manipal University, Manipal- 576104, Karnataka, India.

ABSTRACT
Based on molecular docking studies eight molecules were selected for synthesis. These eight novel quinazolinone
derivatives were synthesized and characterized by spectral analysis. These derivatives were screened for antioxidant
activity, anticancer activity and toxicity studies. Molecular docking of the derivatives was performed using vLife MDS®
4.2 with Epidermal Growth Factor Receptor kinase domain (PDB ID: 1M17) as a target. Docked compounds were
analyzed for molecular interactions. Analog BSQ1 was found to have highest dock score (-76.56) and the binding
interactions of all the other compounds were found to be favourable. Analog BSQ1exhibited mild antioxidant activity
(IC50 175 µg/ml), when compared with ascorbic acid (IC508.71 µg/ml). Analog BSQ8 showed good anticancer activity
on HCT-116 cell line (IC50 11.6 µM) and BSQ1also showed good anticancer activity against MCF-7 cell line (IC50 31.6
µM) which was compared to the positive control doxorubicin.
Keywords: Antioxidant, Anticancer, MTT assay, DPPH method, vLife MDS®
INTRODUCTION
Cancer is still a major health problem and feared disease in
the world today. It is feared because it is difficult to cure.
However since the past decade, a dramatic shift has occurred
in cancer therapy. Despite serious side effects of existing
anticancer drugs, the regular method of chemotherapy still
remains the treatment of choice for many types of cancer,
which include breast, colorectal, lung and pancreatic cancers
as well as lymphoma, leukaemia and multiple myeloma1.
Hence it is a major challenge to design new drugs that will
be more selective for cancer cells with lesser side effects.
Since the last fifty years more than hundreds of natural and
synthetic chemical entities have been tested for anticancer
activity, out of which only about 25 are in wide use today.
This indicates how difficult this problem is2.
Literature review has revealed that Quinazolinone derivatives
are widely used in pharmaceutical industry, medicine and
in agriculture due to their enormous biological activity.
The quinazolinone moiety is versatile nitrogen containing
heterocyclic compound and backbone for nearly 150
naturally occurring alkaloids and drugs. Derivatives of
Quinazolinon-4(3H)-ones are of considerable interest
because of the diverse range of their biological and
* For Correspondence:
E-mail: suvarna.gk@manipal.edu

pharmacological activities like antibacterial3, anti-HIV4,
anti-tubercular5, anticancer6, anti-inflammatory7, antiviral8,
antifungal9, analgesic10, antihistaminic11, antiulcer12,
anticonvulsant13, CNS depressant14, antioxidant15, antimalarial16, antihypertensive17etc. This work is a continuation
of our research on Quinazolinon-4(3H)-ones. In our present
communication, we describe the synthesis, docking and the
evaluation of antioxidant activity by DPPH method and
anticancer activity by MTT assay of someQuinazolinon4(3H)-ones derivatives. As the derivatives were selected
based on the best docking scores and their novelty, we were
able to choose very few compounds for synthesis. Only eight
derivatives were able to synthesise as they were not reported
for anticancer activity. Antioxidant activity was carried out
as there is growing evidence that reactive oxygen species
are involved in the aetiology of fat-related neoplasms such
as cancer of the breast and colorectum due to continued
oxidative stress. The cell lines selected for the study are
breast cancer cell lines, MCF-7 and Human colon epithelium
cancer cell line, HCT-116.
MATERIALS AND METHODS
Materials
The solvents, reagents and chemicals used in the present
work were purchased from Sigma Aldrich, E. Merck,
Spectrochem, and S.D.Fine Chem., Hi-Media and used
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without further purification. TLC was used to check the
purity of the synthesized compounds by using silica gel
60 F254 (E. Merck) aluminum plates. Melting points was
determined using laboratory melting point apparatus
(Toshniwal P. Ltd.) and were uncorrected. IR spectra of the
synthesized compounds were recorded on FT-IRAffinity-1
(Shimadzu) IR Spectrometer. Mass spectra were recorded on
GC-MS-QP5050A (Shimadzu). NMR spectra were recorded
on Bruker 400 MHz spectrometer using DMSO-d6 as the
solvent.

then at room temp 3-4 hour; (ii) Hydrazine hydrate (2
equiv), Pyridine, reflux (120-1300C), 5 hours; (iii) Substituted
aromatic aldehyde (1 equiv), ethanol, glacial acetic acid,
reflux (80-900C), 10 hours.
Synthesis of 2-phenyl-3,1-benzoxazin-4(3H)-one20
Anthranilic acid (0.1mol) was solubilised in 25 ml of dry
pyridine. Benzoyl chloride (0.1mol) was added dropwise with
constant mixing and maintaining temperature of 80C for one

Molecular Docking Studies
Molecular docking was done by GRIP batch docking method
using vlife MDS® 4.2. The crystal structure of Epidermal
Growth Factor Receptor kinase domain (PDB ID: 1M17)
for anticancer docking studies was obtained from the protein
data bank18, 19.The parameter fixed for docking simulation
was - number of placements: 50, rotation angle: 10º, ligand
flexible, exhaustive method, scoring function: dock score.
The ligand forming most stable drug-receptor complex
was the one which was having minimum dock score. After
docking simulation, the best docked conformer of each
ligand was checked for its various interactions with receptor
like hydrogen bonding, hydrophobic bonding and vander
Waal’s interaction. Dock score of the compounds are listed
in Table 2.
Scheme for the synthesis of Quinazolinone derivatives
O

Cl

O

hour. The reaction mixture was mixed for another 5 hours at
room temperature. The reaction was watched over TLC. The
solid obtained was poured into crushed ice and treated with
sodium bicarbonate solution (20%) to remove the unreacted
acid. Once the effervescence reduced, the reaction mixture
was filtered and washed with water to remove inorganic
materials and recrystallized from ethanol.
Synthesis of 3-Amino-2-phenyl-quinazolin-4(3H)-one
2-phenyl-3, 1-benzoxazin-4(3H)-one (0.05mol) was dissolved
in anhydrous pyridine (30ml). To this, hydrazine hydrate
80% (0.1mol) was added drop wise in excess and refluxed
for 8 hours at temperature of 120-1300C under anhydrous
reaction conditions . The reaction was watched over by TLC.

Synthesis of quinazolinone derivatives

C

Reagents and Conditions: (i) Pyridine, stir at 0-80C 1 hour,

When reaction was complete, the mixture was cooled to
room temperature and poured into ice cold water containing

OH

dilute hydrochloric acid. The product was filtered off, rinsed
repeatedly with water, dried and recrystallized from ethanol.

NH2

Melting point was found to be 180-1820C.

(i)
O

Synthesis of 3-(amino substituted arylidene)-2-phenyl-

O

quinazolin-4(3H)-one

N

3-Amino-2-phenyl-quinazolin-4(3H)-one

(0.01)

was

dissolved in ethanol. Ethanolic solution (20ml) of aromatic

(ii)
O

aldehyde (0.01mol) was added to the quinazolinone solution

NH2

and the pH of the resulting solution was adjusted to 4.0-

N

4.5 using glacial acetic acid. This mixture was refluxed for

N

10-12 hours at 110-1200C. The reaction was monitored by

(iii)

TLC. When the reaction was complete, the mixture was

O
N
N

N

CH

R

cooled to room temperature and then poured into ice cold
water. The separated solid was filtered, rinsed with water and
recrystallized from ethanol.Yields and physical characteristics
are listed in Table 1.
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Table 1: Physical data of the quinazolinone derivatives
Compound

R

Mol. Formula

% Yield

Mt.pt (oC)

RfValue

C23H16N4O

80.96

252-254

0.68

C21H13Cl2 N3O

59.69

230-234

0.84

C21H13Cl2 N3O

64.21

230-233

0.87

C22H17N3O

65.59

206-209

0.83

C19H13N3OS

60.95

226-228

0.9

C22H17N3O2

66.61

240-242

0.8

C23H19N3O2

84.80

218-222

0.82

C20H14N4O

58.12

182-185

0.64

N

BSQ1

Cl

Cl

BSQ2

Cl

BSQ3

Cl

BSQ4

CH3

S
BSQ5
H3CO

BSQ6

BSQ7

OC2H5

BSQ8

Spectral data of quinazolinone derivatives
3-[(3H-Indol-3-ylmethylene)-amino]-2-phenyl-3Hquinazolin-4-one (BSQ1): FTIR (KBr, cm-1): 3253.91
(-NH), 3062.96 (C-H, Ar-H), 2924.09 (C-H, Ali-H), 1658.78
(C=O,), 1622.13 (C=N), 1519.91 (C=C); 1H NMR (400MHz,
DMSO-d6): δ = 7.193- 8.635(14H, Ar-H), 11.67(s, 1H, H–
C=N), 11.83(1H, NH); GCMS (EI, m/z): 364(M+).
3-[(2,3-Dichloro-benzylidene)-amino]-2-phenyl-3Hquinazolin-4-one (BSQ2): FTIR (KBr, cm-1):3329.14

(-NH),590.22 (C-Cl), 3055.24 (C-H, Ar-H), 2956.87 (C-H,
Ali-H), 1653.00 (C=O,), 1600.92 (C=N), 1525.69 (C=C);1H
NMR (400MHz, DMSO-d6): δ =7.288- 8.904(14H, Ar-H),
11.85(s, 1H, H–C=N) 11.83 (1H, NH); GCMS (EI, m/z):
393(M+).
3-[(2,4-Dichloro-benzylidene)-amino]-2-phenyl-3Hquinazolin-4-one (BSQ3): FTIR (KBr, cm-1):3217.27
(-NH), 586.88 (C-Cl), 3130.47 (C-H, Ar-H), 2983.88
(C-H, Ali-H), 1654.92 (C=O,), 1604.77 (C=N), 1531.48
(C=C);GCMS (EI, m/z): 393(M+).
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3-[(4-Methyl-benzylidene)-amino]-2-phenyl-3Hquinazolin-4-one (BSQ4): FTIR (KBr, cm-1):3317.55
(-NH), 3062.96 (C-H, Ar-H), 2916.37 (C-H, Ali-H), 1661.07
(C=O,), 1602.86 (C=N), 1537.27 (C=C);GCMS (EI, m/z):
339(M+).
2-Phenyl-3-[(thiophen-3-ylmethylene)-amino]-3Hquinazolin-4-one (BSQ5): FTIR (KBr, cm-1): 3288.63
(-NH), 1178.51 (C-S), 3070.68 (C-H, Ar-H), 2881.65
(C-H, Ali-H), 1658.78 (C=O,), 1647.21 (C=N), 1591.27
(C=C);GCMS (EI, m/z): 331(M+).
3-[(2-Methoxy-benzylidene)-amino]-2-phenyl-3Hquinazolin-4-one (BSQ6): IR (KBr, cm-1):3233.48 (-NH),
1178.51 (C-S), 3070.68 (C-H, Ar-H), 2881.65 (C-H, Ali-H),
1658.78 (C=O,), 1647.21 (C=N), 1591.27 (C=C);GCMS (EI,
m/z): 355(M+).
3-[(4-Ethoxy-benzylidene)-amino]-2-phenyl-3Hquinazolin-4-one (BSQ7):IR (KBr, cm-1):3062.96 (-NH),
2976.16 (C-H, Ar-H), 2893.22 (C-H, Ali-H), 1670.35 (C=O,),
1606.70 (C=N), 1554.63 (C=C);GCMS (EI, m/z): 369(M+).
2-Phenyl-3-[(pyridin-3-ylmethylene)-amino]-3Hquinazolin-4-one (BSQ8): IR (KBr, cm-1): 3057.17 (CH, Ar-H), 2926.01 (C-H, Ali-H), 1645.28 (C=O), 1604.77
(C=N), 1581.63 (C=C),1H NMR (400MHz, DMSO-d6): δ
=7.228- 8.561(12H, Ar-H), 8.904 (s, 1H, H–C=N) 11.87
(1H, CNH); GCMS (EI, m/z):326.12(M+).
BIOLOGICAL ACTIVITY
Antioxidant Activity
Antioxidant activity of the synthesized compounds was
carried out by diphenylpicrylhydrazyl (DPPH) radical
scavenging assay method21. This assay method involved
the use of 96 well microtitre plate in which 100µl of test
sample (the synthesised compounds) and standard solution
(Ascorbic acid) was added to each well separately and in
triplicates. Next, 100µl of DPPH solution was added to
each well. Control wells were loaded with 100µl each of
DMSO and DPPH. Sample blank and control blank were
also performed. The plates were incubated at 37oC for 30
minutes without exposing to light and the absorbance of
each solution was recorded with ELISA reader using 540 nm
filters. The percentage scavenging of test samples at each
concentration was calculated using the following formula:
[(Control absorbance – Test absorbance) / Control
absorbance] X 100
The IC50 was calculated using the Microsoft excel.
24
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Anticancer Activity
The cytotoxic effect of test samples on cancer cell lines
(MCF-7 and HCT-116) was determined by MTT assay
method22. In brief, exponentially growing cells (1 × 104 cells
⁄ well) were plated in 96 well micro titre plates and allowed
to adhere for 24 hour prior to the addition of test samples.
These samples were dissolved in 0.1% DMSO and then
diluted with the medium. The cells were then exposed to
different concentrations of the test samples for 24 hour. The
cells in the control wells received medium containing the
same volume of DMSO (0.1%). After the incubation, 100 µL
of MTT reagent (1 mg ⁄ ml in PBS) was added, and cells were
incubated for an additional 4 hour. The formazan produced
by the viable cells was solubilized by addition of 100 µL
DMSO. The suspension was placed on a microvibrator for
5 min, and the absorbance was recorded at 540 nm by the
plate reader (ELx800; BioTek, Winooski, VT, USA). The
experiment was performed in triplicate. Doxorubicin was
used as positive control. The percentage cytotoxicity of the
synthesized compounds was calculated using the following
formula:
% cytotoxicity = [(Control absorbance – Blank absorbance) –
(Test absorbance– Blank absorbance) ⁄ (Control absorbance–
Blank absorbance)] × 100.
RESULTS
Compound BSQ1 was found with highest dock score
(-76.56) which indicated that it formed the most stable
drug-receptor complex amongst all the eight synthesized
compounds. The docking pose of BSQ1 is shown in Figure
1which represents the hydrogen bonding with amino acid
LYS721A, Vander Waal’s interactions with few amino acid
residues of the receptor and pi stacking interaction with
amino acid PHE699A. Eight molecules with best dock score
were selected for synthesis which were novel as anticancer
activity was not explored for them. All eight compounds were
synthesized by following established synthetic procedure
and their structure was confirmed from spectral data. All the
compounds were screened for antioxidant activity followed
by anticancer activity. Cytotoxicity screening was carried
out against Vero cell lines. Several concentrations ranging
from 31.25-1000μg/ml of the synthesized compounds
were tested for their antioxidant activity by using DPPH
scavenging method. Ascorbic acid was used as the standard.
The IC50 value of the compounds for antioxidant activity
are shown in the Table 2. Among the tested compounds
BSQ1 and BSQ6 showed antioxidant activity with IC50

Manipal Journal of Pharmaceutical Sciences • September 2015 (Volume 1, Issue 1)

4

Kumari et al.: Synthesis, Molecular Docking and Biological Evaluation of Some Qu
Suvarna G Kini, et al: Syntheis, molecular docking and biological evaluation

value of 175 and 835μg/ml respectively. The IC50 of all
other compounds were above 1000μg/ml. These results
showed that antioxidant activity of all eight synthesized
compounds was mild when compared with IC50 of ascorbic
acid (8.75μg/ml). The anticancer activity was done by MTT
assay on MCF-7 and HCT-116 cell lines. Compound BSQ1
showed good anticancer activity in MCF-7 cell line with IC50
31.6µM/ml compared with IC50 of Doxorubicin (1.1µM/
ml). Compound BSQ8 showed good anticancer activity in
HCT-116cell line with IC50 11.6µM/ml compared with IC50
of Doxorubicin (0.6µM/ml). All the synthesised compounds
showed IC50 value of more than 100µM/ml against VERO
cell line indicating that the compounds are safe till 100µM/
ml whereas the standard drug doxorubicin had IC50 value
of 4.8µM/ml. Figure 2 and Figure 3 shows the graphical
representation of IC50 for antioxidant activity of selected
compounds and also the graphical representation ofIC50 for
anticancer activity of all eight compounds against MCF-7
and HCT-116 cell lines.

B

C

A

Figure 1: Docking poses of BSQ1 with the EGFR receptor pdb
code 1M17.( A shows hydrogen bond interaction in green colour
of the molecule with amino acid LYS721A , B shows vanderWalls
interaction in pink colour with number of amino acid residues of
the receptor and C shows pi stacking interaction in yellow colour
with amino acid PHE699A of the receptor residue).
Table 2: Docking and Biological activity Results of Quinazolinone derivatives
Compound
Dock Score
Anti-oxidant IC50 (µg/ml)
MCF-7 IC50 (µM/ml)
HCT-116 IC50(µM/ml)
BSQ1
-76.56
175±0.96
31.6±0.86
26.9±1.00
BSQ2
-58.11
>1000±1.05
84.9±1.18
23.9±0.83
BSQ3
-73.22
>1000±2.71
>400±0.75
124.4±0.93
BSQ4
-71.14
>1000±1.83
68.0±1.80
30.2±1.48
BSQ5
-69.18
>1000±3.23
51.3±1.15
63.1±4.80
BSQ6
-73.22
835±1.05
>400±1.98
27.0±2.60
BSQ7
-74.68
>1000±4.17
>400±0.98
>400±1.90
BSQ8
-67.16
>1000±2.10
201.7±0.80
11.6±0.55
Ascorbic acid
_
8.75±0.78
_
_
Doxorubicin
_
_
1.1±2.40
0.6±3.35
Values are means of triplicate samples (n = 3). Data are presented as the mean ± SEM.
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VERO IC50(µM/ml)
>100±1.75
>100±1.25
>100±1.35
>100±1.18
>100±1.78
>100±1.85
>100±4.18
>100±1.15
_
4.8±2.65
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